- Home
- FBNC vs KOD Comparison
FBNC vs KOD Comparison
Compare FBNC & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FBNC | KOD |
|---|---|---|
| Founded | 1934 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.3B |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FBNC | KOD |
|---|---|---|
| Price | $63.12 | $41.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $62.25 | $35.43 |
| AVG Volume (30 Days) | 297.8K | ★ 787.2K |
| Earning Date | 04-22-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | ★ 45.65 | N/A |
| EPS | ★ 1.13 | N/A |
| Revenue | ★ $67,623,000.00 | N/A |
| Revenue This Year | $37.82 | N/A |
| Revenue Next Year | $2.30 | N/A |
| P/E Ratio | $55.99 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $45.04 | $6.21 |
| 52 Week High | $66.54 | $47.84 |
Technical Indicators
Market Signals| Indicator | FBNC | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 49.69 | 55.56 |
| Support Level | $61.78 | $39.37 |
| Resistance Level | $66.30 | $46.72 |
| Average True Range (ATR) | 1.52 | 2.96 |
| MACD | -0.29 | -0.04 |
| Stochastic Oscillator | 41.00 | 60.79 |
Price Performance
Historical ComparisonAbout FBNC First Bancorp
First Bancorp is a bank holding company. The company is engaged in providing commercial and consumer banking services, mortgage lending, SBA lending, accounts receivable financing, and investment advisory services.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.